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Interleukin 2 (IL-2), 1  also known as T cell growth factor, discovered by Morgan 
et al.  (1),  is a  lymphokine produced by normal peripheral blood  lymphocytes 
after antigen or mitogen stimulation (2, 3) and is required for the proliferation 
and function of T  cells (2,  3),  natural killer cells (4-6),  and cytotoxic effector 
cells in vitro and in vivo (7-9).  In addition,  IL-2 is able to induce or enhance 
gamma interferon production by T  cells (10,  11) and granulocyte-macrophage 
colony-stimulating factor (Platzer, E., K. Welte, and M. A. S. Moore, manuscript 
in preparation). IL-2 is also produced by fresh lymphoblastic leukemic cells (12) 
and T  cell leukemia cell lines (13). 
We have demonstrated that IL-2 restores partially or completely the defective 
proliferative response of T  cells from patients with congenital immunodeficien- 
cies (14),  acquired immunodeficiency syndrome (15),  and patients  after bone 
marrow transplantation (16). 
Several  laboratories  including our own  have purified  IL-2  to  homogeneity 
(17-19).  Depending on  the  cellular  source  and  stimulation  conditions,  IL-2 
shows a  molecular heterogeneity with molecular weights between  14,500  and 
17,000  and  isoelectric  points  between  6.8  and  8.2  (17,  20).  The  molecular 
heterogeneity is most likely due to variations of glycosylation of the molecule 
(18,  20).  Recombinant DNA  technology has provided  recombinant IL-2  (21) 
with biochemical and biological characteristics similar to those of native IL-2 
(22, 23). 
Recently, a  murine monoclonal antibody termed anti-Tac (24) was shown to 
be able to block the binding of IL-2 to the IL-2 receptor-positive human T  cell 
line HUT  102 (25), and the cellular binding site for IL-2 was demonstrated to 
be identical with the Tac antigen, which is a glycoprotein of 58,000 mol wt (26). 
OKT3  antibody recognizes 95%  of peripheral blood  T  lymphocytes and is 
mitogenic in concentrations between 0.1  and 1,000 ng/ml for total T  cells (27) 
and T  cell subpopulations (28). As recently demonstrated on T  cell clones (29), 
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the T  cell antigen receptor is a single complex consisting of the T3 molecule of 
20,000-25,000  mol wt and a  clonotypic, disulfide-linked heterodimer (Ti) with 
a  molecular weight of 90,000.  Anti-T3 (or OKT3 antibody) therefore triggers 
the proliferation of T  cells in a way similar to antigen (30). 
We studied the induction of Tac antigen expression with low concentrations 
of OKT3 antibody, which do not induce IL-2 production and no cell prolifera- 
tion.  Under  these  conditions,  the  expression of Tac  antigen  is  dependent  on 
exogenous IL-2, suggesting that IL-2 might induce its own receptor. 
Material and  Methods 
Monoclonal Antibodies.  OKT3 antibody was purchased from Ortho Pharmaceutical, 
Raritan, NJ. Anti-Tac antibody (ascites fluid) was kindly provided by Dr. T. Waldmann, 
National Insitute of Health. Monoclonal antibody against gamma interferon was prepared 
by one of us as described (31). 
Mononuclear  Cells from Peripheral Blood (PBMC).  PBMC from healthy human volun- 
teers were separated by density gradient centrifugation on FicolI-Hypaque according to 
the method of Boyum (32). Cells were washed three times in RPMI  1640, supplemented 
with  2  mM  L-glutamine,  50  U/ml  penicillin,  50  ttg/ml  streptomycin, and  10%  heat- 
inactivated  fetal  calf serum.  Cells  were  kept  in  this  medium  during  all  subsequent 
incubation and washing procedures. 
Adherent  Cells.  For adherence, up to 3 ×  107 PBMC were incubated for 90 min at 
37°C in 5% CO2 in a total volume of 10 ml of Falcon tissue culture dishes (No. 3003; 
Falcon Labware, Oxnard, CA).  Nonadherent cells were collected by gently swirling the 
dishes and slowly pipetting off the medium. Dishes were washed three times with medium, 
and adherent cells were harvested using a rubber policeman. The adherent cell fraction 
contained 80-95% monocytes/macrophages as judged by aiphanaphthyl-acetate-esterase 
stain. 
Separation of T Cells.  For isolation of T  cells, nonadherent PBMC were rosetted with 
neuraminidase-treated sheep erythrocytes according to a method modified from Weiner 
et al. (33). This fraction contained <2% monocytes/macrophages and was 90-98% positive 
for OKT3. This cell population is subsequently called "E  + cells". 
Treatment  With Mitomycin C or Emetine.  For some studies,  PBMC  or E  + cells  were 
treated with mitomycin C (Sigma Chemical Co., St. Louis, MO) or emetine-HCl (Sigma 
Chemical Co.) before addition to cultures.  Mitomycin C  is an irreversible inhibitor of 
DNA synthesis (34).  Emetine is an irreversible inhibitor of protein synthesis at the level 
of translation (35). Therefore, the use of emetine was preferred over cycioheximide, since 
it allows  the pulse exposure. Cells  were incubated at concentrations of 2  ×  10S/ml  in 
culture medium containing 25/,g/ml mitomycin C for 30 min at 37°C, or in 5 ×  10  -6 M 
emetine-HC1 for 2 h at 37 °C. After washing three times, cell concentrations were adjusted 
for viability as determined by trypan blue dye exclusion (viability >70% after all treat- 
ments). 
Analysis of T Cell Surface Antigens (OKT3, Tac) With the Fluorescence-activated Cell Sorter 
(FACS).  Immunofluorescence analyses were performed on a FACS IV (Becton, Dickinson 
& Co., Mountain View, CA).  For indirect immunofluorescence, 106 cells were incubated 
with  appropriate dilutions of monoclonal antibodies (1:10,000 for anti  Tac;  1:40  for 
OKT3) for 40  min at  4°C,  washed twice, and then incubated with a  1:40 dilution of 
affinity-purified goat anti-mouse IgG, F(ab')2-fluorescein isothiocyanate (FITC) (Cappel 
Laboratories, Cochranville, PA) in the same way. After washing twice, cells were brought 
up in 1 ml phosphate-buffered saline for FACS analysis. All incubation and centrifugation 
steps were done at 4 o  C. Background fluorescence was determined using diluted normal 
mouse serum instead of first antibody. 
Simultaneous Staining  of DNA and RNA.  By simultaneous staining of DNA and RNA 
with acridine orange the following measurements were obtained: the number of living 
cells, the number of dead cells, the number of cells in Go and G~ phases, the number of 1392  REGULATION  OF  TAC  ANTIGEN  EXPRESSION  BY  INTERLEUKIN  2 
cells in S phase,  the number of cells in G~ plus M  phases,  and the mean quantity of 
stainable RNA per cell in the subpopulation of G1, S and G2 plus M. All cells were stained 
and measured under the same conditions (36). The measurements were performed on a 
modified Ortho cytofluorograf FC 201 (Ortho Diagnostic Systems, Westwood, MA). 
Simultaneous Staining of DNA and Surface Antigens.  Cells were prepared in the same 
way as for FACS analysis (see above), fixed in  70%  ethanol, treated with RNase, and 
counterstained for DNA with propidium iodide (PI) as previously described (37). Green 
fluorescence (FITC-labeled secondary antibody plus Tac antibody), red fluorescence (PI- 
DNA),  and red pulse width (nuclear diameter) were simultaneously measured on 5,000 
cells per sample and analyzed using a Nova 1220 minicomputer. Red pulse width (RPW) 
allows us to discriminate single cells from cell aggregates; only single cells were analyzed 
for cell cycle distribution and Tac antigen expression. Multiparameter data analysis was 
done  using programs  developed  in  the  Laboratory of Investigative Cytology, Sloan- 
Kettering Institute, New York. 
Proliferation Assay.  The separated E  ÷ cells (supplemented with 10% macrophages) or 
PBMC (106 cells/ml) were incubated in triplicate microwell cultures (No. 3596 culture 
plate; Costar, Cambridge, MA) in the presence or absence of mitogen (OKT3 antibody) 
and in the presence or absence of exogenous, highly purified IL-2. The concentrations 
used were: OKT3, 2.5 ng/ml (optimal concentration), 250 pg/ml, 25 pg/ml (low concen- 
tration), 2.5 pg/ml; IL-2, 20 U/ml, 200 U/ml, 2,000 U/ml. At indicated time points, 100 
#1 of supernatant were removed from each well to be assayed for IL-2 activity. After 72 
h, identical cultures were pulsed for 4 h with [SH]thymidine (0.5 #Ci/well; New England 
Nuclear, Boston, MA) and the [SH]thymidine uptake measured as described previously 
(28). 
Assay for IL-2 Activity.  For the IL-2 assay, murine IL-2-dependent cytotoxic T  cells 
(CTLL  1) (38)  were  used as previously described (17).  Recently, the  NIH  Biological 
Response  Modifiers Program  has  made available an  IL-2  standard.  One  unit of this 
standard is equivalent to one unit of IL-2 as previously described (17, 38). 
Preparation of Purified Human IL-2.  The purification of IL-2 from lymphocyte-condi- 
tioned medium (Ly-CM) has been described in detail (17). For this study we used Ly-CM 
purchased from Folex-Biotest-Schteussner, Inc., Fairfield, NJ.  IL-2 was purified by se- 
quential ammonium sulfate precipitation, anion exchange chromatography (DEAE cellu- 
lose, DE 52; Whatman Laboratory Products, Clifton, NJ), gel filtration on AcA 54 (LKB 
Instruments, Inc., Rockland, MD), and chromatography on blue agarose and on procion- 
red agarose (both, Bethesda Research Laboratories, Gaithersburg, MD). The final product 
had a specific activity of 106 U/mg protein and was free of detectable interferon (alpha 
and gamma) activities,  granulocyte-macrophage colony-stimulating  activity, B cell growth 
factor, and B cell differentiating activities.  In two of six experiments detailed in Table II 
and two of five experiments shown in Fig. 1, recombinant IL-2, purified to homogeneity 
(specific activity, 2 ×  106 U/mg protein) and kindly provided by AMGen, Thousand Oaks, 
CA, was used in parallel with highly purified IL-2. Recombinant IL-2 and highly purified 
I L-2 gave qualitatively  and quantitatively identical results in these experiments. Therefore, 
results are detailed for highly purified IL-2 only. 
Preparation of Human  Gamma Interferon.  Gamma interferon was purified from Ly- 
CM. The final product had a specific activity of 107 NIH units/mg protein. 
Results 
IL-2 Production and Proliferation  of PBMC or E + Cells Plus Macrophages  Stimu- 
lated with Various  Concentrations  of OKT3 Antibody.  As shown previously (28), 
OKT3  antibody at  concentrations of 1 ng/ml or more  induces maximal IL-2 
production at day 1 and maximal proliferation measured as [3H]thymidine uptake 
in PBMC at day 3 of culture (28) (Fig.  1).  As shown in Fig.  1, OKT3 antibody 
at a concentration of 250 pg/ml is still able to induce near optimal proliferative 
responses  of  PBMC  in  the  absence  or  presence  of exogenous  IL-2.  OKT3 WELTE  ET  AL.  1393 
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FXGURE  l.  Mitogenic effect of different concentrations (2.5 pg/ml to 25 ng/ml) of OKT3 
on PBMC in the presence (==) or absence (O) of IL-2 (20 U/mi). Each point is the median and 
range of five independent experiments. [3H]Thymidine uptake was measured  on clay 3 of 
$  culture. For each experiment, [ H]thymidine incorporation obtained with the optimal OKT3 
concentration (2.5  ng/m[)  in  the  absence of exogenous  IL-2 (82,000-112,000  cpm)  was 
considered as 100%. 
antibody at a concentration of 25 pg/ml is not able to induce IL-2 production 
(not shown) or substantial  proliferation (Fig.  1).  The  maximal [SH]thymidine 
uptake at this concentration is  10%  of the cpm reached with optimal  OKT3 
concentrations. However, in the presence of exogenous IL-2 (20 U/ml or more), 
this OKT3 antibody concentration leads to at least half of the maximal prolifer- 
ation obtained with optimal OKT3 antibody concentrations. OKT3 antibody in 
concentrations of 2.5 pg/ml is not sufficient to induce a mitogenic response even 
in the presence of exogenous IL-2. 
The proliferative response to OKT3 antibody at all concentrations tested was 
the same for E  + cells supplemented with 10% macrophages as for PBMC. Optimal 
IL-2 production and proliferative response of E  ÷ cells required the presence of 
at least  10%  macrophages.  Interestingly, however, the presence of 3%  macro- 
phages was not sufficient for the induction of IL-2 production but was sufficient 
for E  + cells to acquire IL-2 responsiveness when stimulated with OKT3 antibody 
at concentrations of 25 pg/ml or higher. IL-2 production and proliferation in 
response to OKT3 antibody were identical when E + cells with 10% macrophages 
or PBMC were used. Therefore, we performed all further studies with PBMC. 
Cell cycle analysis was performed on PBMC after 3 d in culture in the absence 
or presence of IL-2. In the absence of OKT3 antibody, <3% of PBMC were in 
S  +  G2/M  phase,  both  with and without  IL-2.  When stimulated with optimal 
OKT3 antibody concentrations, >20% of PBMC were in S +  G~/M phase in the 
absence or presence of exogenous IL-2. However, PBMC stimulated with 25 pg/ 
ml OKT3  antibody entered S  phase only in  the presence of exogenous IL-2 
(13.2% in S +  G~/M phase vs.  1.6% in the absence of IL-2) (Table I, Fig. 3). 
Time  Kinetics  of  Proliferation  Induced  by  Low  OKT3  Antibody  Concentra- 
tions.  Using 25 pg/ml of OKT3 antibody did not result in a significant increase 
of either I L-2 production (not shown) or [3H]thymidine uptake of the cells within 
the first 6  d  in culture when compared with medium control (Fig.  2).  Even at 
day  3,  when  maximal  proliferation  was  seen  with  optimal  OKT3  antibody 
concentrations,  <10%  of maximal  proliferation  occurred.  IL-2  alone  (in  the 1394  REGULATION  OF  TAC  ANTIGEN  EXPRESSION  BY  INTERLEUKIN  2 
TABLE  I 
Percentage of Cells in Go/G1 or S + Ge/M Phase of the Cell Cycle at Day 3 of Culture 
Percentage of PBMC in: 
Go/Gl phase  S +  G~/M phase 
[SH]Thymidine uptake 
(cpm X 10 -3) 
-IL-2  +IL-2  -IL-2  +IL-2  -1L-2  +IL-2 
Medium  99.1  97.3  0.9  2.7  0.3  2 
OKT3, 25 pg/ml 
Untreated cells  98.4  86.8  1.6  13.2  4  40 
Mitomycin C-treated cells  98.7  98.0  1.3  2.0  0.2  0.2 
OKT3, 2.5 ng/ml  79.3  74.6  20.7  25.4  93  101 
Cells are unstimulated (medium) or stimulated with OKT3 antibody (25 pg/ml, 2.5 ng/ml), cultured 
in the absence or presence of exogenous IL-2 (20  U/ml), and analyzed by cytofluorometry after 
staining with acridine orange. 
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FIGURE 2.  Time course of proliferation of PBMC stimulated with OKT3 antibody (25 pg/ 
ml) in the presence (11) and absence (O) of exogenous IL-2 (20 U/ml). The proliferation of 
unstimulated cells in the presence of exogenous IL-2 is also shown (x). 
absence of OKT3 antibody) led to an increase of proliferation starting at day 4 
of culture (12,000 cpm) and to subsequently increasing cell proliferation ([~H]- 
thymidine uptake at day 6,  25,000  cpm; Fig. 2), suggesting there were few IL- 
2-responsive cells in the starting cell population. OKT3 antibody (25 pg/ml) in 
combination with exogenous IL-2 (20  U/ml), however, led to a sharp increase 
of DNA synthesis and cell division already at day 3 of culture (45,000 cpm) with 
a subsequently increasing proliferation (Fig.  2) and long-term growth (>2 mo) 
of T  cells by repeated addition of IL-2 to the cultures. 
Since  the difference between proliferation  in  the presence and  absence  of 
exogenous IL-2 was most pronounced at day 3 of culture, and IL-2 alone did 
not lead to substantial proliferation at this time point, we used cells after 3 d  in 
culture, stimulated with 25 pg/ml OKT3 antibody, for all further studies. 
Tac Antibody Immunofluorescence.  The number of Tac  + cells was examined on 
days 1-3 of culture in the presence or absence of IL-2 and containing (a) medium 
alone, (b) 25 pg/ml OKT3 antibody, or (c) 2.5 ng/ml OKT3 antibody. As shown 
in Table  II, in the absence of IL-2  and without stimulation, <5%  of the cells 
were Tac  +. IL-2 alone did not significantly increase the percentage of Tac  + cells. WELTE  ET  AL. 
TABLE II 
Percentage of Tac  ÷ PBMC at Day 3 of Culture 
1395 
PBMC  PBMC 
PBMC  (mitomycin C  (emetine treated) 
treated) 
-IL-2  +IL-2  -IL-2  +IL-2  -IL-2  +IL-2 
Medium  <5  <6  NT  NT  NT  NT 
OKT3 
25 pg/ml  6 (4-6)*  23 (18-28)*  7  21  <5  <5 
2.5 ng/ml  39 (30-46)*  46 (39-49)*  38  40  <5  <5 
Cells are unstimulated (medium) or stimulated with OKT3 antibody (25 pg]ml, 2.5 
ng/ml). The viability of PBMC at the initiation of and at day 3 of culture was >70% 
in all experiments and regardless of treatment with mitomycin C or emetine. NT, not 
tested. 
* Results from six independent  experiments are shown as median and range. 
TABLE III 
Time Kinetic of Tac Antigen Expression 
OKT3  OKT3 
(25 pg/ml)  (2.5 ng/ml) 
-IL-2  +IL-2  -IL-2  +IL-2 
Day 1  4.6  6.0  14.1  18.8 
Day 2  4.5  12.4  24.4  26.7 
Day 3  6.7  21.5  30.1  39.5 
PBMC were cultured  in the presence of OKT3 antibody (25 pg/ml, 2.5 
ng/ml),  and in the presence or absence of IL-2 (20 U/ml).  Results are 
expressed as percent Tac  ÷ PBMC as determined by FACS analysis. 
Using OKT3  antibody in a  concentration  of 25 pg/ml, the percentage of Tac  + 
cells was still 6% or less in the absence of IL-2 at days 1-3 in culture (Table III); 
however, upon stimulation with exogenous IL-2, 6% of PBMC were Tac  + at day 
1,  12.4%  at  day  2,  and  21.5%  at  day  3.  In  five additional  experiments  using 
OKT3  antibody at a  concentration  of 25  pg/ml,  between  4  and  6%  of PBMC 
were Tac  + at day 3 of culture in the absence of exogenous IL-2, and between  18 
and  28%  of PBMC  were Tac  + in  the  presence of exogenous  IL-2. Stimulation 
with optimal OKT3 concentrations (2.5 ng/ml) led to between 14 and 19% Tac  + 
cells  in  the  absence  or  presence  of exogenous  IL-2,  respectively,  at  day  1  of 
culture,  24  and  27%,  respectively,  at  day  2  of  culture,  and  30  and  40%, 
respectively, at day 3 of culture (Table III). In five additional experiments using 
optimal  OKT3  antibody  concentrations,  the  number  of Tac  +  cells  were  39% 
(range,  30-46%)  or 49%  (range,  39-56%)  in the absence or presence of IL-2, 
respectively. Control experiments showed that OKT3  antibody at all concentra- 
tions used in this study did not result in detectable background immunofluores- 
cence. 
Simultaneous  Staining  of DNA  and  Tac  Antigen.  As  shown  in  Fig.  3,  the 
independently  achieved results of proliferative response and  the  percentage of 
Tac  ÷ cells were confirmed by measuring simultaneously DNA fluorescence and 
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FIGURE  3.  Simultaneous  measurement  of cellular  DNA  fluorescence  (propidium  iodide- 
stained DNA) and immunofluorescence obtained by staining with Tac antibody plus F(ab')~- 
FITC goat anti-mouse IgG. (Top) Pattern when 25 pg/ml OKT3 antibody was used; (bottom) 
pattern when 2.5 ng/ml OKT3 antibody was used. (Left) Pattern in the absence of exogenous 
IL-2; (right) pattern in the presence of exogenous IL-2 (20 U/ml). 
for stimulation with  low OKT3  antibody concentrations (25  pg/ml).  The left 
side of the upper panel demonstrates that the cells in the absence of exogenous 
IL-2 do not enter S phase and do not express Tac antigen. In the presence of 
exogenous IL-2  (right side, upper panel),  -13%  of PBMC entered S +  G2/M 
phase.  All  of them  showed  immunofluorescence with  Tac  antibody.  Using 
optimal OKT3 antibody concentrations, as shown in the lower panel of Fig. 3, a 
significant proportion of cells expressed Tac and proliferated, as detailed above. 
Even at  this  concentration of OKT3  antibody,  however,  the  density of Tac 
antigen was higher in the presence of IL-2 than in its absence. 
Effect of DNA Synthesis and Protein Synthesis Inhibitors on the Appearance of Tac + 
Cells in OKT3-stimulated Cultures.  As shown in Table II, treatment with mito- 
mycin C,  a  DNA synthesis inhibitor,  for 30  min at  37°C  did not change the 
appearance of Tac  ÷ cells in the OKT3-stimulated cell population compared with 
untreated cells. The majority of cells, however, did not enter the S or G2M phase 
of the cell cycle (Table II). The expression of Tac antigen can be attributed to 
exogenous IL-2 since (a) the concentration of OKT3 antibody used (25 pg/ml) 
did not lead to endogenous IL-2 production and (b) there is no or very low Tac 
antigen expression in the absence of exogenous IL-2 (Fig. 3). 
Treatment  of the  cells  with  emetine,  an  irreversible  inhibitor  of protein 
synthesis,  for  2  h  at  37°C  resulted  in  the  total  prevention  of Tac  antigen 
expression at all concentrations of OKT3 antibody used in our study, suggesting 
the requirement for protein synthesis for Tac antigen expression. WELTE  ET  AL.  1397 
TABLE  IV 
Effect of Exogenous IL-2 on Tac Antigen Expression and 
[ 3H]thymidine Uptake 
[SH]thymidine uptake 
IL2  Tac  + cells  (cpm X 10 -~) 
U/ml  % 
0  <5  7 
20  23  69 
200  28  71 
2,000  18  62 
PBMC were stimulated with OKT3 antibody (25 pg[mi) in the presence 
or absence of varying concentrations of IL-2. Percentage of Tac  + cells was 
determined by FACS analysis. 
Effect of Different Concentrations of lL-2 on Tac Antigen Expression.  As shown 
in Table IV, the number ofTac  + cells in PBMC stimulated with 25 pg/ml OKT3 
antibody and  IL-2 at concentrations  of 20, 200, and 2,000 U/ml were 23, 28, 
and  18%, respectively. The corresponding [SH]thymidine uptakes were 69,000, 
71,000, and 62,000 cpm, respectively. In the absence of IL-2, <5% of the cells 
were Tac + and the [SH]thymidine uptake was 7,100 cpm. 
Role of Gamma Interferon in the Responsiveness to IL-2 and Tac Antigen Expres- 
sion.  Since some evidence has been reported (39) that gamma interferon plays 
a role in IL-2 receptor expression, we studied the effect of highly purified gamma 
interferon and monoclonal antibody against gamma interferon on T  cell respon- 
siveness  to  IL-2  and  Tac  antigen  expression.  Neither  gamma  interferon  in 
concentrations  of  20,  40,  and  100  U/ml  nor  anti-gamma  interferon  (100 
neutralizing  units/ml)  significantly altered  the proliferative  response to exoge- 
nous  IL-2  or the percentage  of Tac  ÷ cells under  our experimental  conditions 
(data not shown). 
Discussion 
In  this  study we describe the effect of low, nonmitogenic  concentrations  of 
OKT3 antibody in combination with optimal concentrations of exogenous IL-2 
on the proliferation  of PBMC or E ÷ cells (supplemented with  10% autologous 
macrophages).  We have  chosen  this  combination  because  (a)  OKT3  antibody 
alone at this  concentration  does not induce measurable endogenous  IL-2 pro- 
duction, allowing us to study the effect of exogenous IL-2, (b) it does not induce 
IL-2  receptor expression as measured  by Tac antibody FITC  immunofluores- 
cence  analysis,  and  (c)  exogenous  IL-2  in  combination  with  this  low  OKT3 
antibody concentration leads to proliferation of PBMC or E + cells in the presence 
of macrophages.  Therefore,  we consider this a  good model to study the effect 
of exogenous IL-2 on Tac expression without interference by endogenous IL-2 
(the possibility that  IL-2 induces its own production is under investigation).  IL- 
2 alone was not able to induce proliferation and Tac antigen expression within 
the first 3 d of cultures (Fig. 2). 
We used OKT3 as stimulus because OKT3 antigen is associated with or is part 
of the  T  cell  antigen  recognition  complex  (29).  Therefore,  stimulation  with 1398  REGULATION  OF  TAC  ANTIGEN  EXPRESSION  BY  INTERLEUKIN  2 
OKT3 antibody triggers  IL-2 production and proliferation  of T  cells in a  way 
analogous  to  antigenic  stimulation.  In  a  concentration  of 25  pg/ml,  OKT3 
antibody is not able to induce proliferation or Tac expression (Figs.  1, 3) but in 
combination  with  exogenous  IL-2  there  is  Tac  expression  and  a  proliferative 
response.  However, only about half of the maximal proliferation obtained with 
optimal  OKT3  concentrations  is seen  under  these conditions,  as measured  by 
both [3H]thymidine  uptake and  the percentage  of cells in  S +  Ge/M phase by 
flow cytometry. 
The observation that OKT3 antibody does not induce IL-2 production at 25 
pg/ml is consistent with a recent report (30) that for IL-2 production and release 
by a cloned T  cell line, T  cell antigen receptor crosslinking is required, whereas 
for IL-2 receptor expression, T  cell antigen receptor crosslinking is not required. 
OKT3 at concentrations of 25 pg/ml, or ~10 molecules of IgG per cell under 
our experimental  conditions,  is  not  likely  to  be able  to  crosslink  the  antigen 
receptor and, therefore, IL-2 production will not occur. 
We studied  the  effects of exogenous  IL-2  in  combination  with  low OKT3 
antibody concentrations on the proliferation  of PBMC over a  period of 6 d  in 
cultures (Fig.  2).  We chose day 3 for most of our more detailed  studies,  since 
optimal  OKT3  concentrations  induce maximal  proliferation  at  this  time point 
under our experimental conditions (28) and exogenous IL-2 alone in the absence 
of mitogens is still  without effect on proliferation on day 3. 
Whether this difference between proliferation in the presence and absence of 
IL-2 might be used as a  simple IL-2 assay to determine the amount of IL-2 in 
mitogen-free unknown samples is under study. Preliminary results demonstrate 
that  as  low as 0.5  U/ml  IL-2 can  be detected with  this  assay system, which  is 
comparable  in  sensitivity to  the  murine  cytotoxic T  lymphocyte line  (CTLL) 
assay (38 and data not shown). 
The difference in responsiveness of PBMC at day 3 of culture to low OKT3 
antibody  concentrations  (25  pg/ml)  in  the  presence  and  absence  of  IL-2  is 
consistent with the different number of Tac  + cells detected under these condi- 
tions. In the absence of IL-2, the same number of cells were Tac  ÷ in the medium 
control and in low OKT3 antibody concentrations (6% or less). However, in the 
presence of IL-2, the control medium also showed only 6% Tac + cells, whereas 
with IL-2 in combination with low OKT3 antibody concentrations,  18 and 28% 
of the cells were Tac +. 
To address the question whether Tac  ÷ T  cells are derived from a small number 
of Tac  ÷ cells present  at  the  initiation  of cultures  and  grown  up  in  the  IL-2- 
containing  medium,  we  treated  T  cells  with  mitomycin  C.  Treatment  with 
mitomycin C, a potent inhibitor of DNA synthesis, still allowed for expression of 
Tac antigen  to the same extent as without treatment (Table II), but prevented 
the cells from entering DNA synthesis and cell division (Table I). This suggests 
that IL-2 in combination with low OKT3 antibody concentration does not simply 
lead to proliferation  of preexisting Tac  + cells, resulting in a  higher  number of 
Tac + cells at day 3. Rather, it induces the expression of Tac antigen on previously 
Tac- cells that need not necessarily enter DNA synthesis. 
Further evidence that Tac  + cells do not simply derive from Tac  + cells present 
at the initiation of culture is that, after stimulation with optimal OKT3 antibody WELTE  ET  AL.  1399 
concentrations, a high percentage of Tac  + cells were already present at day 1 of 
culture, when [3H]thymidine uptake was still low or not detectable and cells had 
not entered the S phase of the cell cycle. Since after stimulation with optimal 
OKT3 concentrations, maximal IL-2 production occurs at day 1 of culture (28), 
the Tac antigen expression at this time might also be due to endogenous IL-2. 
Similar results were reported by Uchiyama et al. (24), where concanavalin A was 
used as mitogen. It was also reported by the same group (24) that treatment of 
the cells with anti-Tac antibody plus complement before initiation of culture did 
not abolish the appearance of Tac  + cells when stimulated with a mitogen or in a 
cytotoxicity assay. 
The receptor induction seems dependent on protein synthesis, since pretreat- 
ment with emetine, an irreversible inhibitor of protein synthesis at the level of 
translation, prevented any proliferative response to IL-2 and expression of Tac 
antigen, without influencing the percentage of viable cells significantly. 
In summary, the results obtained in  our study strongly suggest that IL-2  is 
involved in the induction of its own receptor. Tac antigen expression appears to 
be a  two-step event: preactivation by OKT3  of cells capable of activating Tac 
antigen, which sensitizes these cells to the Tac-inducing effects of IL-2. IL-2 is 
then required for the full expression of functionally active Tac antigen, leading 
to cell proliferation. Among the possible mechanisms explaining this phenome- 
non  are  the  following:  (a)  OKT3  antibody  in  low  concentration  (25  pg/ml) 
triggers an activation of the IL-2 receptor not detectable by the Tac antibody 
immunofluorescence technique. As a second step, the presence of exogenous IL- 
2 results in the expression of the Tac antigen, now detectable with Tac antibody. 
(b) Binding of OKT3 antibody, even at this low concentration, may lead to an 
alteration of the cell membrane polarity by influencing the ion influx or efflux 
(e.g., Ca  ++) and the presence of IL-2 in the medium then triggers activation of 
Tac antigens in the altered membrane. (c) Another membrane antigen may react 
with IL-2 that is distinct from the Tac antigen and that may also be required for 
IL-2-driven proliferative responses. This would be consistent with a report (40) 
about a T  cell antigen reacting with IL-2 on guinea pig T  cells that is different 
from the IL-2 receptor. This complex distinct from the IL-2 receptor might play 
a critical role in the initial processing of the IL-2 signal. IL-2 might activate this 
distinct antigen  which,  in  concert with  the activated T3  complex or antigen 
recognition complex, then leads to the Tac antigen expression. 
The  observation  that  low  concentrations  of OKT3  antibody,  even  in  the 
presence of optimal IL-2  concentrations (up to 2,000  U/ml), will  only lead to 
half-maximal Tac expression and proliferation suggests that only a subpopulation 
of PBMC  is able to respond under these conditions, while other cells require 
higher concentrations of OKT3 antibody to acquire IL-2 responsiveness. 
We cannot exclude the possibility that IL-2 regulates the expression of its own 
receptor via another lymphokine or monokine, such as receptor-inducing factor 
or gamma interferon. Johnson and Farrar (39) reported that gamma interferon 
is able to induce the expression of IL-2 receptors on human peripheral blood T 
cells. We therefore studied the effect of highly purified gamma interferon in 
concentrations between 20 and 100 U/ml and anti-gamma interferon monoclo- 
nal antibody (100  neutralizing units) in the presence and absence of IL-2 and 1400  REGULATION OF  TAC  ANTIGEN EXPRESSION BY  INTERLEUKIN 2 
low OKT3 antibody concentrations (25 pg/ml). There was no significant altera- 
tion of proliferation, measured by [3H]thymidine uptake at day 3 of culture or 
by the percentage of Tac  ÷ cells at the same time point, suggesting no major role 
for gamma interferon  in  Tac  induction  under  our  experimental  conditions. 
These  results  are  at  variance  with  the  findings of Johnson  and  Farrar  (39), 
possibly due to differences in experimental conditions. 
Results similar to the effects of low concentrations of OKT3 antibody com- 
bined  with  exogenous  IL-2  on  normal  PBMC  were  obtained  with  optimal 
concentrations of OKT3  on  PBMC from patients with leukemia and aplastic 
anemia after bone marrow transplantation. The proliferative response of PBMC 
to OKT3 antibody (2.5 ng/ml) from 23 patients was 8,000 cpm (median) in the 
absence of exogenous IL-2 and 51,000 cpm (median) in the presence of exoge- 
nous I L-2 (16). This suggests a functional defect of the transplanted lymphocytes 
or their precursors in these patients. The near-normal response in the presence 
of exogenous IL-2, however, would be consistent with the fact that IL-2 is able 
to induce its own receptor even on these functional defective cells,  leading to 
proliferation of the cells. 
It  would  be  of great  interest  to  know  whether  IL-2  can  regulate  its own 
receptor  expression  also  in  vivo.  We have  initiated studies to  investigate the 
percentage of Tac  + total PBMC and T  cell subsets from patients with immuno- 
deficiency states who are enrolled in our ongoing phase 1 trial of IL-2 (41). 
Summary 
We investigated the effect of OKT3 antibody and interleukin 2 (IL-2) on Tac 
antigen expression and the proliferation of  human peripheral blood mononuclear 
leukocytes. OKT3 monoclonal antibody at low, nonmitogenic concentrations (25 
pg/ml) or IL-2 alone at optimal concentrations (20  U/ml) did not induce IL-2 
receptor expression, as  measured by Tac antibody or by T  cell proliferation. 
However, costimulation with these concentrations of OKT3 antibody and IL-2 
led to Tac antigen expression and T  cell proliferation. These data suggest that 
the T  cells  are  activated in  two steps:  OKT3  antibody at 25  pg/ml does not 
induce Tac antigen expression, but preactivates T  cells to become responsive to 
IL-2.  The  addition  of exogenous  IL-2  then  leads  to  expression  of the  IL-2 
receptor, as recognized by Tac antibody, and to subsequent proliferation. 
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